Shares of Celgene Corporation (NASDAQ:CELG) hit a new 52-week high on Thursday . The stock traded as high as $141.84 and last traded at $141.87, with a volume of 2,549,061 shares trading hands. The stock had previously closed at $140.16.

Several analysts have recently weighed in on CELG shares. Leerink Swann upgraded shares of Celgene Corporation from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $94.42 to $150.00 in a research report on Friday, June 16th. They noted that the move was a valuation call. Goldman Sachs Group, Inc. (The) reiterated a “sell” rating and set a $98.00 target price (up from $93.00) on shares of Celgene Corporation in a research report on Wednesday, May 17th. William Blair reiterated an “outperform” rating on shares of Celgene Corporation in a research report on Monday, June 26th. BTIG Research lowered shares of Celgene Corporation from a “buy” rating to a “neutral” rating and lifted their target price for the company from $96.93 to $131.70 in a research report on Friday, June 30th. Finally, Canaccord Genuity set a $156.00 target price on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Monday, May 22nd. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and twenty-two have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $147.31.

The company has a market capitalization of $110.42 billion, a P/E ratio of 43.71 and a beta of 1.89. The firm has a 50-day moving average price of $134.00 and a 200 day moving average price of $126.47.

Celgene Corporation (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.21. The business had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The firm’s quarterly revenue was up 18.7% on a year-over-year basis. During the same quarter last year, the business earned $1.44 EPS. On average, analysts anticipate that Celgene Corporation will post $7.32 EPS for the current year.

In related news, Director Michael D. Casey sold 9,250 shares of the firm’s stock in a transaction that occurred on Monday, June 19th. The shares were sold at an average price of $125.59, for a total value of $1,161,707.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ernest Mario sold 18,506 shares of the firm’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the completion of the transaction, the director now owns 69,424 shares of the company’s stock, valued at approximately $9,061,220.48. The disclosure for this sale can be found here. In the last quarter, insiders sold 263,011 shares of company stock valued at $35,078,473. 0.95% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. raised its holdings in Celgene Corporation by 5.7% in the 2nd quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock valued at $7,366,919,000 after buying an additional 3,084,227 shares during the last quarter. Vanguard Group Inc. raised its holdings in Celgene Corporation by 3.1% in the 2nd quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock valued at $6,951,579,000 after buying an additional 1,610,056 shares during the last quarter. State Street Corp raised its holdings in Celgene Corporation by 2.3% in the 1st quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock valued at $4,040,668,000 after buying an additional 723,844 shares during the last quarter. Jennison Associates LLC raised its holdings in Celgene Corporation by 1.2% in the 2nd quarter. Jennison Associates LLC now owns 13,415,734 shares of the biopharmaceutical company’s stock valued at $1,742,301,000 after buying an additional 156,864 shares during the last quarter. Finally, FMR LLC raised its holdings in Celgene Corporation by 5.9% in the 2nd quarter. FMR LLC now owns 12,594,467 shares of the biopharmaceutical company’s stock valued at $1,635,643,000 after buying an additional 697,250 shares during the last quarter. Institutional investors and hedge funds own 79.43% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Celgene Corporation (CELG) Hits New 12-Month High at $141.84” was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/07/celgene-corporation-celg-hits-new-12-month-high-at-141-84.html.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.